Compare USAS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | LBRX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2004 | 2025 |
| Metric | USAS | LBRX |
|---|---|---|
| Price | $4.66 | $42.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.50 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 4.4M | 241.5K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $174.68 | N/A |
| Revenue Next Year | $53.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $13.40 |
| 52 Week High | $10.50 | $50.16 |
| Indicator | USAS | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 46.94 |
| Support Level | $4.51 | $22.85 |
| Resistance Level | $5.19 | $49.74 |
| Average True Range (ATR) | 0.28 | 2.05 |
| MACD | -0.09 | -0.83 |
| Stochastic Oscillator | 11.58 | 7.64 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.